Clinical Trial Update: A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical trial evaluating a dual-targeting tracer TATE-RGD for imaging SSTR- and RGD-positive tumors. The study targets iodine-resistant thyroi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma
• Neuroendocrine Tumor
• Thyroid Cancer

Drugs mentioned

• TATE-RGD dual-targeting tracer (TATE-RGD tracer)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Iodine-resistant Thyroid Cancer, Meningioma | EARLY_Phase 1 | Status: RECRUITING